ArticleScientific reports2025
Discovery of anti-inflammatory compounds from the stem bark of Garcinia latissima through in vitro and in silico approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Garcinia latissima Miq. has been traditionally used by local communities in Indonesia for wound healing and to relieve itching. A phytochemical investigation of the stem bark of G. latissima led to the isolation of 12 tocotrienol and triterpenoid derivatives, including two previously undescribed metabolites, δ-(E)-deoxy-amplexichromanoyl acetate (1) and (20S,24S)-20,24-epoxylanostane-3β,25-diol (2), whose structures were elucidated using HRESIMS and NMR spectroscopic analyses. Among the isolates, (20R)-eupha-8,25-diene-3β,24ξ-diol (11) suppressed nitric oxide production in LPS-stimulated RAW 264.7 cells by more than 60% at concentrations of 10 and 50 µM, without significant cytotoxicity (cell viability > 80%). It also reduced the release of several inflammatory mediators, particularly MCP-1, as determined by a membrane antibody array. ELISA confirmed a significant decrease in MCP-1 levels, up to 2.3- and 2.8-fold at 3 and 24 h, respectively, following pre-treatment with compound 11 at 50 µM. Molecular docking and molecular dynamics simulations indicated a strong binding affinity of compound 11 to MD2, TAK1, and NF-κB1, key proteins in the TLR-4 signaling pathway, with predicted affinities higher than those of reference ligands. ADMET analysis further suggested favorable drug-like properties, including high predicted oral bioavailability and minimal toxicity. These findings suggest that compound 11 has promising anti-inflammatory potential, warranting further experimental studies to elucidate its mechanism of action and to validate its effects in additional inflammation-related bioassays.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.